BV2 

BV2 is a delivery peptide that binds to BVES, with a K_a of 2.03 μM for the BVES target. BV2 specifically binds to the extracellular domain of BVES, achieving muscle homing and cellular internalization via caveolae-mediated endocytosis. When BV2 is modified on the surface of exosomes by PMO, it enhances dystrophin restoration in the peripheral muscles and myocardium of dystrophin-deficient mice. BV2 is applicable to research related to Duchenne muscular dystrophy and muscle atrophy^[1].

BV2 (15.625-2000 nM) binds specifically to the extracellular domain of BVES with a dissociation constant of 2.03 μM^[1].
BV2 (0.5-10 μg/mL; 15 min-6 h) is taken up by C2C12 mouse myoblasts in a dose- and energy-dependent manner, localizes to the cytoplasm and early endosomes, and is internalized primarily via caveolae-mediated endocytosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Rhodamine B-labelled BV2 (10 mg/kg; i.v.; single dose) demonstrates strong muscle-homing ability in wild-type C57BL/6 mice, with preferential accumulation in cardiac and skeletal tissues after single intravenous administration of 10 mg/kg^[1].
BV2-mCherry (20 mg/kg; i.v.; single dose) effectively delivers mCherry protein to peripheral skeletal muscle cells in wild-type C57BL/6 mice after single intravenous administration of 20 mg/kg, with minimal accumulation in non-muscle tissues^[1].
Rhodamine B-labelled BV2 (100 μg per microneedle patch; local implantation; single application; 2 hours), delivered via HA microneedle implantation, effectively accumulates in and is internalized by local skeletal muscle cells in wild-type C57BL/6 mice after a single 2-hour application of a 100 μg-loaded patch^[1].
BV2-mCherry (150 μg per microneedle patch; local implantation; single application), delivered via HA microneedle implantation, effectively promotes mCherry protein delivery to skeletal muscle layers in wild-type C57BL/6 mice after a single application of a 150 μg-loaded patch^[1].
BV2-E31R (50 μg per microneedle patch; local implantation; 3 times per week; 2 weeks), delivered via HA microneedle implantation at 50 μg per patch 3 times weekly for 2 weeks, significantly increases muscle mass and myofibre size in both immobilization- and denervation-induced skeletal muscle atrophy mice^[1].
EXOBV2&PMO (12.5 mg/kg/week PMO equivalent; i.v.; weekly; 3 weeks), administered intravenously at 12.5 mg/kg/week PMO equivalent for 3 weeks, significantly restores dystrophin expression (up to 10-fold increase in triceps), enhances muscle grip strength, and reduces muscle damage in adult mdx mice^[1].
EXOBV2&PMO (25 mg/kg/week PMO equivalent; i.v.; weekly; 3 weeks), administered intravenously at 25 mg/kg/week PMO equivalent for 3 weeks, achieves near-normal dystrophin restoration in peripheral muscles, partial cardiac dystrophin restoration, and significant phenotypic rescue (improved grip strength, reduced muscle damage) in adult DKO mice without detectable organ toxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1307.50

C₅₇H₉₈N₁₈O₁₇

Ser-Ser-Val-Thr-Arg-Val-Gly-Tyr-Leu-Arg-Gly-Ile

SSVTRVGYLRGI

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang B, et al. Cardiac and skeletal muscle delivery of biotherapeutics with a blood vessel epicardial substance-targeting peptide. Biomaterials. 2026;329:123986.  [Content Brief]